On Pharma

October 26, 2006

Wyatt to Appeal Ruling re: Viscotek

Filed under: Miscellany, Process Analytical Technology — pharmamanufacturing @ 12:44 p.10.

SANTA More drama in an unlikely place: laboratory instrumentation (Now, who says this is a staid and dull business?)  

Last week we touched on this story. What impact could this have on the engineer whose emails were involved?

Wyatt Technology Corporation has filed an appeal to the 9th Circuit Court of Appeals to reverse the recent decision by the California Central District Federal Court. “The decision that our Company was wire tapping when it read eMail messages sent to its own computer by defendant Viscotek is certainly in error and will be reversed,” said Dr. Philip Wyatt Chief Executive Officer. “In addition,” Wyatt added “we look forward to recovering our wrongfully-taken property and damages from Viscotek—well in excess of $5,000,000—once the case is sent back for trial.”

-AMS

October 22, 2006

Novartis Flu Vaccine Snafu Shows Need to Extend “Op Ex” to Contract Drug Manufacturing

Filed under: FDA and Regulatory Issues, Miscellany, Operational Excellence, Process Safety, The Pharma Industry — pharmamanufacturing @ 12:44 p.10.

If drug manufacturing efficiency varies inversely with the degree of manufacturing complexity, contract drug manufacturing and packaging operations must be the most complex of all.  Can they always be efficient? Contractors, after all, must adapt constantly to shifting products, clients, and key customer markets/regulatory requirements.

Leading contract organiztions do what they do very well, but they may still slip up sometimes.  The latest evidence was reported on yesterday, when The Washington Post disclosed that Novartis had recalled  500,000 doses of flu vaccine after it was found that they had been frozen.  (Click here to read the story). This apparently took place when the vials were in the custody of its contract partner, Cardinal Health.

Cardinal is looking into what might have caused the problem. 

But it made me think that more drug companies should extend their in-house manufacturing excellence programs beyond their company borders—that they should have the same standards in place, and they should track performance regularly, and impose  penalties when standards aren’t met.

Not to suggest that there are structural problems at Cardinal, which has a very good record, or that Novartis isn’t fully committed to op ex.

But formal programs that do this are very difficult to start up and maintain.  It’s hard enough to measure data and keep up with metrics at your own facility, and some contractors may resent too much supervision. 

But it can be done. We reported recently on the work that one group at Wyeth was doing to set standards and ongoing metrics for its partners.  Are more efforts like this going on? Please write in and let us know.

-AMS

Connecting Patients and Drug Plant Operators: A Public Relations Lesson From Talecris

Filed under: Miscellany, Operational Excellence, The Pharma Industry — pharmamanufacturing @ 12:44 p.10.

Remember the proposal (was it Glaxo’s?) to help improve the industry’s standing by having its drug sales reps go out and talk to patients about all the great work that the industry (and company) are  doing?  No offense to drug reps, but it sounds like a doomed P.R. plan to me. Because drug reps are, after all, selling the final product…they aren’t involved in discovering or making it.

Just read about a far more useful approach, and an  interesting project that the biotherapeutics manufacturer, Talecris, pulled off last month:  It invited patients taking some of its plasma-based therapies to tour  its manufacturing plant in Clayton, N.C.  The company paid their travel and other expenses.

Not only did that give patients some understanding of the drug manufacturing process (something rarely talked about, with all the emphasis on R&D), but the visit  likely reinforced, to those working at the facility, the reasons why they’re working in the first place and the fact that their jobs are important.

The article notes that some of Talecris’ therapies are highly specialized, and the company does not advertise on television, hence it needed more outreach.

But, seriously, couldn’t this be the way for all drug companies to educate the public about drug manufacturing, while incenting their plant workforce?  Pick a random sampling of patients and invite them to see how it’s really done? The costs would be much lower than those for requiring new spin doctors or PR/ad campaigns.  And hearing from the specialists and operators themselves would certainly beat hearing PR speak from a sales rep.

The article added to the evidence that Talecris is doing some extremely interesting things, in general, and as far as “manufacturing science” goes:  Its process analytical technology (PAT) program, for example, is outstanding and unusually well thought out.

-AMS

October 20, 2006

Life Saving Tip for the Season?

Filed under: Miscellany — pharmamanufacturing @ 12:44 p.10.

OK, brief digression here.

“Life saving” may be a slight exaggeration, but “face saving” isn’t: a slip of the knife has led to many a Jack O’Lantern fiasco, and disappointed kids.  Here are very basic tips on “How to Carve a Pumpkin” as well as patterns for the more adventurous.

Collaboration Would Allow Industry to Mine Data, and Apply Lessons, From Macher and Nickerson’s Research

This Wednesday, I interviewed Georgetown and Washington University professors Macher and Nickerson, whose research into FDA and drug manufacturing efficiencies was recently reported ( and mentioned in a previous post).  Their research stems from a study of the semiconductor industry that they did while graduate students in California. (It will be interesting to contrast findings from the two studies; We’ll feature the interview and summarize benchmarking lessons in our next issue of Pharmaceutical Manufacturing).

This first phase of their research suggests that increasing manufacturing complexity has a negative impact on drug yields and cycle times. 

Given that increasing complexity is an inescapable reality for the industry, especially as it moves to “personalized medicine” and combination devices, the need for better management of drug manufacturing operations is urgent. 

As Professor Macher noted, the most complex semiconductor process involves between 400 and 500 process steps; some AIDS medications today already require 100 to 150 manufacturing steps.

Their research suggests that drug companies could save well over $50 billion* a year by improving manufacturing—allowing them to invest more in discovery and R&D, and reduce the cost of drugs to the consumer.

It also suggests that FDA is definitely moving in the right direction with many of its new initiatives: notably risk-based enforcement and the Inspectorate Training program. To watch/listen to an audio/powerpoint presentation summarizing findings, click here.

Georgetown and Washington university paid for the research, and neither professor received any additional reimbursement for this work, ensuring that the data are truly trustworthy and relevant. (more…)

October 19, 2006

Trade Secret Theft and Your Job: Ruling in Recent Case Underscores Need for Caution

Filed under: Miscellany — pharmamanufacturing @ 12:44 p.10.

Recent news about the spying and improprieties going on at Hewlett-Packard obscured an interesting bit of news and a reminder that spying may also take place on much smaller stages, and even in the rarified world of laboratory instrumentation.

Instrumenta just published a report on a case involving California-based Wyatt Technology Corp.,  Viscotek Corp. (Houston) and dynamic light scattering (DLS) technology.

Wyatt sued Viscotek last year for trade secret theft, but according to the report, U.S. District Court Judge Dickran Tevrizian in Los Angeles dismissed Wyatt’s complaint but also ruled that Wyatt  had “intentionally accessed a Viscotek employee’s private emails without authorization, and obtained protected information” relating to DLS technology.

Wyatt must now pay punitive damages of $100K and another $200K+ in legal costs., both to Viscotek and to its U.K. based employee Ken Cunningham. 

There’s more to this story, but I’d like to focus on Mr. Cunningham, because what happened to him can happen to anyone when they change jobs, and are caught in the middle of complex cross-company IP ownership and licensing issues.

Wyatt had bought some DLS technology assets from Proterion. Viscotek had entered the DLS business by licensing single-mode fiber DLS technology, which had previously been licensed to Proterion by a third party, Instrumenta reported.  (Wyatt didn’t buy this portion of the Proterion DLS package, since it uses multimode fiber in its instrumentation).

Proterion employee Cunningham provided some freelance services to existing Proterion customers after Wyatt acquired the DLS technology.  But when he joined Viscotek, his computer became Wyatt’s property and the company apparently accessed all his personal (non-Proterion) emails, some of which contained sensitive information.

Employees who change jobs (and move to a competitor) are often suspected—rightly or wrongly—of taking trade secrets with them, one reason why noncompete agreements are frequently so limiting (unreasonably so). 

Should employees as a matter of course, delete all sensitive emails, even personal email that might be on the company computer, to protect themselves from potential liability before they change jobs (or is this even enough anymore?)  Or should one simply opt never, ever to send or access personal email accounts using the company computer? What do you think?

-AMS

Ultrasonic Scientific, Innovative Spectroscopy Vendor, Is Up For Sale

Filed under: Miscellany, Process Analytical Technology — pharmamanufacturing @ 12:44 p.10.

Just read in the latest issue of Instrumenta’s monthly analytical insrument industry report (www.instrumenta.com) that Ultrasonic Scientific has been put up for sale.  The four-year-old, Dublin based company had commercialized technology pioneered by former Max Planck Institute scientist Vitaly Buckin,  and  had been doing some innovative work in ultrasonic spectroscopy, which has advantages over traditional optical methods in analyzing opaque liquids. Process Analysis and Automation Ltd. (Farnborough, U.K.) offers ultrasonic spectroscopic technologies.

Apparently the company, which had recently set up a marketing office in the U.S., was unable to establish an effective marketing, sales and distribution network.  This is a problem that several of the most creative analytical instrumentation companies appear to suffer from. 

Note to any companies that might meet this description: Your brilliant technology will mean nothing if nobody hears about it. 

For an update that appeared in the local Irish financial press, please click here.  

Good-bye, Anna Russell (or, When Comedy Was Smart)

Filed under: Miscellany — pharmamanufacturing @ 12:44 p.10.

To take a very brief break from pharma, just learned today that the comedienne extraordinaire, Anna Russell, died yesterday in Australia. 

Her comedy career spanned from the 1950s through the 1980s. I’m sure that most people under the age of 27 might find her work, at best, ”quaint.”  After all, we live in an age of short attention spans, and brilliant, but chameleon-like comedic actors like Robin Williams and Jim Carey who shift in seconds from persona to persona, or from gag to gag.

Her work drew from a wellspring of knowledge (a deep knowledge of music history, theory and performance) and didn’t patronize its audience.

Listening to Ms. Russell’s parody of Wagner’s Ring Cycle is as good an introduction to that formidable work as any “serious” music appreciation class, and her “How to Write Your Own Gilbert and Sullivan Operetta” stands on its own.   For an audio bio of Ms. Russell (roughly 30 minutes long) narrated by the great Lilly Tomlin, click here.

Ms. Russell wasn’t all that well known, outside of hard-core classical music circles, so I include a smattering of some very brief audio clips and some parody lyrics .

Better known, but operating in the same vein, was the great Danish pianist Victor Borge.  Both, clearly, must have inspired Peter Schickele and PDQ Bach. They also showed that comedy doesn’t always have to aim for the least common denominator, to work.

-AMS

Monitoring Workplace Hazards and Operator Performance in Real Time

Filed under: Miscellany, Process Safety, The Pharma Industry — pharmamanufacturing @ 12:44 p.10.

Pharmaceutical Manufacturing just published an article on Professor Jim McGlothlin’s work at Purdue University’s Exposure Assessment Research Laboratory. 

McGlothlin and graduate students at his PEARL lab have developed an extremely useful tool PEARL VEM and how it works that allows workplace hazards (such as particulates, emissions, noise—and human responses such as heart rate) to be recorded in real time, while videos show how operators are using process equipment.  

VEM may not eliminate the need for air sampling, but would allow such sampling to be used more strategically, says McGlothlin. It also allows top control priorities to be established.

Users access the wireless system (which involves a laptop PC, sensors and video camera) via a specific IP address; sensor and video data are sent simultaneously to the PC…With this equipment, a company could “vet” a contract API manufacturer halfway across the world.  Information can also be stored for future training.

 Could the use of such technology smack of “Big Brother?”  Perhaps, but it could prove to be a powerful tool in preventing operator error and increasing safety.  The story appears below….

.

Monitoring Indoor Air Pollution in Real Time

 

Pharma facilities may not be thought of as environmentally hazardous work environments. After all, GMP and strict safety regulations prevail, and much attention is paid to avoiding cross-contamination.

 

Yet, the batch processing areas of drug development and pilot plants, particularly those that focus on tableting and solid dosage forms, can pose hidden hazards.  And sometimes they’re not that hidden either— for instance, when particulates are made airborne by an operator who doesn’t know how to apply local exhaust ventilation effectively.

 

Hazardous active pharmaceutical ingredients (HAPI) aren’t the problem, either, explainsPurdueUniversity professor John McGlothlin, who has been studying particulate exposure for several years. “Generally, the higher the ingredient’s potency, the more careful operators are about handling it,” he says.  “It’s the less potent materials that can accumulate to have a potentially adverse effect.”

 

Given that a large portion of pharma’s workforce is female and of childbearing age, protection is critical.  But it also makes good economic sense, by preventing the cross-contamination that can destroy batches, as well as the waste that occurs when powders accumulate on the floor and must be vacuumed up.

 

What’s especially interesting about the work that McGlothlin and the 10 graduate students in his
PEARL laboratory are doing, is the fact that they are applying video exposure monitoring, in a system that includes a sensor, wireless air sampling and video to analyze workplace hazards, and pinpoint the most troubling areas, in real time.  Years ago, they’d used radio relay, but now wireless technology and the Internet are expanding the power and potential reach of this technique. 

 

Users access the system via a specific IP address; sensor and video signals are conveyed simultaneously to a wireless laptop computer, where data are collected and analyzed. The cost is minimal, requiring only the computer, sensors, video camera and server, but the Web interface  allows global access to real time data, and video, from anywhere in the world. Users can also archive and recall information and use it in future training materials or control systems.

 

What Purdue provides is proprietary software and a caching system, as well as data encryption. “It’s like a car kit,” says McGlothlin.

 

The online monitoring technology won’t eliminate the need for dedicated sampling, an expensive procedure that costs hundreds of dollars each time.  But it allows one to use such sampling more strategically, and to place additional controls at high-risk process points.

 

Having such a visual tool has surprised even McGlothlin by what it has revealed.  His team has found, for instance, that 90% of the exposure risk typically occurs at only 10% of the points within a given work area and cycle.  In tableting operations, for example, the greatest risk of exposure tends to occur in mixing areas, in areas where ingredients are charged from drums into the mixer. 

 

Typically, McGlothlin explains, a local exhaust system is placed near a mixer, but if the operator doesn’t hold the exhaust hose at just the right position near the funnel, particulate concentration can quickly build up in the room.  “It’s not a matter of being six inches or one foot off.” says McGlothlin. “Sometimes just a few inches make a big difference.”

 

The key is consistency in placement of the hose, so that it’s close to the area where the powders are added, but not too close—it should be at the edge of the scoop so that it doesn’t intrude into the scoop.

 

Video exposure monitoring serves as an excellent training tool, McGlothlin says, but also offers automatic incentives and reinforcement for use of best practices.  For example, if monitoring shows that operators have used best practices to lower exposure risks, they may not have to wear as much protective gear the next shift.  When they don’t use the right techniques, they must wear additional gear.

 

The project has evolved over time, and McGlothlin is working with the National Science Foundation (NSF) and the Center for Pharmaceutical Processing Research (CPPR) to commercialize the technology. 

 

So far, each of the CPPR’s 36 members has access to the video exposure monitoring system, and they are sharing findings every few months. McGlothlin’s lab is also applying the technology in a wide variety of other fields and industries, to monitor other environmental factors and responses, including noise and heart rate.

-AMS 

Chromatography: Will Supercritical Replace Simulated Moving Bed

Filed under: Miscellany — pharmamanufacturing @ 12:44 p.10.

Lester Dolak discusses supercritical fluid chromatography in an editorial on Pharmaceutical Online.  What do you think?  Any replacement would likely take quite a while.

But this is only one potential application for supercritical fluids. For an update on “tunable solvents” from Georgia Tech pioneers, read on, and for a review by Angelo De Palma, click here.

Older Posts »

Blog at WordPress.com.